A Phase 2 interventional study of Oxytocin nasal spray in Autism Spectrum Disorder, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-05-18.
Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing oxytocin in Autism Spectrum Disorder — 2 open to participants now, 2 under way, none of them phase 3. Oxytocin · Autism Spectrum Disorder.
Among the 23 studies testing oxytocin in Autism Spectrum Disorder, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 13 in phase 2, and was the 22nd registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →2 of the 23 studies testing oxytocin in Autism Spectrum Disorder are open now, in 2 countries. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 12–20
By country, each count listing its studies:
Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 3 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 30 is below the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 30 across the 23 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 23 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 3 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies testing oxytocin in Autism Spectrum Disorder that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05864508University Hospital, ToulouseInterest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study. | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing oxytocin in Autism Spectrum Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigation team propose in this study to specifically evaluate the feasibility of using oxytocin in the form of an intranasal spray in a specific population of children with autism spectrum disorder and intellectual disability. The lack of studies centered on this population on the one hand, and on the other hand the severity of challenging behaviors presented by these children, make questionable the direct transfer of methods of care used in patients who do not present these challenging behavior. In this sense, the establishment of oxytocin treatment in these children requires a preliminary phase of feasibility assessment before being able to consider a comparative trial of the randomized clinical trial type.
Taking into account:
the investigation team propose in this study to specifically evaluate the feasibility of using oxytocin in the form of an intranasal spray in a specific population of children with autism spectrum disorder and intellectual disability. The lack of studies centered on this population on the one hand, and on the other hand the severity of challenging behaviors presented by these children, make questionable the direct transfer of methods of care used in patients who do not present these challenging behavior. In this sense, the establishment of oxytocin treatment in these children requires a preliminary phase of feasibility assessment before being able to consider a comparative trial of the randomized clinical trial type.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria respecting the Syntocinon SPC:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intranasal oxytocin treatment once a day during 6 weeks
Drug: Oxytocin nasal spray
intranasal oxytocin treatment once a day during 6 weeks
percentage of children with complete OT administration protocol
percentage of children who will complete the OT administration protocol
Time frame: Week 14
percentage of children with complete monitoring protocol
percentage of children who will complete the monitoring protocol
Time frame: week 14
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2023; primary completion for Dec 2026, 41 months later.
Of 68 non-industry phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 41 months is close to that.
Counting every sponsor, half of 83 studies reached it within 36 months; a quarter within 23 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxytocin
University Hospital, Toulouse →